Synoptics Health, a new division of Synoptics, a developer and manufacturer of digital imaging systems for scientific applications based in Cambridge, UK, will unveil its ProReveal test, a rapid in-situ fluorescence-based method of detecting proteins on surgical instruments at Medica in Düsseldorf, Germany.
The patented, ultra-sensitive ProReveal test combines a test kit and viewer with an easy-to-use touch screen and software. In just two simple spray and see steps, users can detect nanogram levels of protein contamination, no matter where it is located on a surgical instrument, in less than 5 minutes.
The product aligns with the protein contamination testing recommendations in the UK’s new NHS CFPP-01-01 consultation document.
The ProReveal test has been developed over four years in partnership with scientists at Queen Mary University of London and is available in the UK from Peskett Solutions of Eastbourne and across the rest of the world from Synoptics Health.
Paul Ellwood, CEO of Synoptics Health, said: “The ProReveal test uses very sensitive, yet cost-effective fluorescence technology and will tell you exactly where, and how much protein is on your surgical instrument. This is a significant quality enhancement from current testing available and there isn’t any other affordable fluorescence-based test designed for this application that is commercially available, so it really is a first at Medica.”
In addition to Synoptics Health, Synoptics has three other divisions: Syngene; Syncroscopy and Synbiosis, of which Syngene is the largest.
Syngene produces advanced systems for molecular biologists to analyse and document fluorescent DNA on gels. Syncroscopy and Synbiosis specialise in digital imaging solutions for microscopy and microbial applications respectively.
